Profil
Dr. Bianca Brundel is Chief Scientific Officer at NYKEN BV.
He received his graduate degree from the University of Amsterdam and a doctorate degree from the University of Groningen.
Ehemalige bekannte Positionen von Bianca Brundel
| Unternehmen | Position | Ende |
|---|---|---|
Nyken BV
 Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Bianca Brundel
| University of Amsterdam | Graduate Degree |
| University of Groningen | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Nyken BV
Nyken BV Pharmaceuticals: GenericHealth Technology Nyken BV develops heat-shock-protein drugs for treatment of chronic diseases. Its products include NYK-1001, a drug that is used for the treatment of gastric discomfort and gastric bleeding in China, Japan, and internationally, NYK-1005, a chemical derivative that is used for atrial myocyte screening and drug identifying discovery system and NYK-1007, an early drug candidate used in heat shock proteins. The company was founded by Herman Steen in 2009 and is headquartered in Groningen, the Netherlands. | Health Technology |
